BRUGGMANN, P., T. BERG, A. L. H. ØVREHUS, C. MORENO, C. E. Brandão MELLO, F. ROUDOT-THORAVAL, R. T. MARINHO, M. SHERMAN, S. D. RYDER, J. SPERL, U. AKARCA, I. BALIK, F. BIHL, M. BILODEAU, A. J. BLASCO, M. BUTI, F. CALINAS, J. L. CALLEJA, H. CHEINQUER, P. B. CHRISTENSEN, M. CLAUSEN, H. S. M. COELHO, M. CORNBERG, M. E. CRAMP, G. J. DORE, W. DOSS, A. S. DUBERG, M. H. EL-SAYED, G. ERGÖR, G. ESMAT, C. ESTES, K. FALCONER, J. FÉLIX, M. L. G. FERRAZ, P. R. FERREIRA, S. FRANKOVA, J. GARCÍA-SAMANIEGO, J. GERSTOFT, J. A. GIRIA, F. L. Jr. GONÇALES, E. GOWER, M. GSCHWANTLER, M. Guimarães PESSÔA, C. HÉZODE, H. HOFER, Petr HUSA, R. IDILMAN, M. KÅBERG, K. D. E. KAITA, A. KAUTZ, S. KAYMAKOGLU, M. KRAJDEN, H. KRARUP, W. LALEMAN, D. LAVANCHY, P. LÁZARO, P. MAROTTA, S. MAUSS, M. C. Mendes CORREA, B. MÜLLHAUPT, R. P. MYERS, F. NEGRO, V. NEMECEK, N. ÖRMECI, J. PARKES, K. M. PELTEKIAN, A. RAMJI, H. RAZAVI, N. REIS, S. K. ROBERTS, W. M. ROSENBERG, R. SARMENTO-CASTRO, C. SARRAZIN, D. SEMELA, G. E. SHIHA, W. SIEVERT, P. STÄRKEL, R. E. STAUBER, A. J. THOMPSON, P. URBANEK, I. van THIEL, H. Van VLIERBERGHE, D. VANDIJCK, W. VOGEL, I. WAKED, H. WEDEMEYER, N. WEIS, J. WIEGAND, A. YOSRY, A. ZEKRY, P. Van DAMME, S. ALEMAN and S. J. HINDMAN. Historical epidemiology of hepatitis C virus (HCV) in selected countries. JOURNAL OF VIRAL HEPATITIS. HOBOKEN: WILEY-BLACKWELL, 2014, vol. 21, Supplement 1, p. 5-33. ISSN 1352-0504. Available from: https://dx.doi.org/10.1111/jvh.12247.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Historical epidemiology of hepatitis C virus (HCV) in selected countries
Authors BRUGGMANN, P. (756 Switzerland), T. BERG (276 Germany), A. L. H. ØVREHUS (208 Denmark), C. MORENO (56 Belgium), C. E. Brandão MELLO (56 Belgium), F. ROUDOT-THORAVAL (250 France), R. T. MARINHO (620 Portugal), M. SHERMAN (124 Canada), S. D. RYDER (826 United Kingdom of Great Britain and Northern Ireland), J. SPERL (203 Czech Republic), U. AKARCA (792 Turkey), I. BALIK (792 Turkey), F. BIHL (756 Switzerland), M. BILODEAU (124 Canada), A. J. BLASCO (724 Spain), M. BUTI (724 Spain), F. CALINAS (620 Portugal), J. L. CALLEJA (724 Spain), H. CHEINQUER (76 Brazil), P. B. CHRISTENSEN (208 Denmark), M. CLAUSEN (208 Denmark), H. S. M. COELHO (76 Brazil), M. CORNBERG (276 Germany), M. E. CRAMP (826 United Kingdom of Great Britain and Northern Ireland), G. J. DORE (36 Australia), W. DOSS (818 Egypt), A. S. DUBERG (752 Sweden), M. H. EL-SAYED (818 Egypt), G. ERGÖR (792 Turkey), G. ESMAT (818 Egypt), C. ESTES (840 United States of America), K. FALCONER (752 Sweden), J. FÉLIX (620 Portugal), M. L. G. FERRAZ (76 Brazil), P. R. FERREIRA (76 Brazil), S. FRANKOVA (203 Czech Republic), J. GARCÍA-SAMANIEGO (724 Spain), J. GERSTOFT (208 Denmark), J. A. GIRIA (620 Portugal), F. L. Jr. GONÇALES (76 Brazil), E. GOWER (840 United States of America), M. GSCHWANTLER (40 Austria), M. Guimarães PESSÔA (76 Brazil), C. HÉZODE (250 France), H. HOFER (40 Austria), Petr HUSA (203 Czech Republic, guarantor, belonging to the institution), R. IDILMAN (40 Austria), M. KÅBERG (752 Sweden), K. D. E. KAITA (124 Canada), A. KAUTZ (56 Belgium), S. KAYMAKOGLU (792 Turkey), M. KRAJDEN (124 Canada), H. KRARUP (208 Denmark), W. LALEMAN (56 Belgium), D. LAVANCHY (756 Switzerland), P. LÁZARO (724 Spain), P. MAROTTA (124 Canada), S. MAUSS (276 Germany), M. C. Mendes CORREA (76 Brazil), B. MÜLLHAUPT (756 Switzerland), R. P. MYERS (76 Brazil), F. NEGRO (756 Switzerland), V. NEMECEK (203 Czech Republic), N. ÖRMECI (792 Turkey), J. PARKES (826 United Kingdom of Great Britain and Northern Ireland), K. M. PELTEKIAN (124 Canada), A. RAMJI (124 Canada), H. RAZAVI (840 United States of America), N. REIS (620 Portugal), S. K. ROBERTS (36 Australia), W. M. ROSENBERG (826 United Kingdom of Great Britain and Northern Ireland), R. SARMENTO-CASTRO (620 Portugal), C. SARRAZIN (276 Germany), D. SEMELA (756 Switzerland), G. E. SHIHA (818 Egypt), W. SIEVERT (36 Australia), P. STÄRKEL (56 Belgium), R. E. STAUBER (40 Austria), A. J. THOMPSON (36 Australia), P. URBANEK (203 Czech Republic), I. van THIEL (56 Belgium), H. Van VLIERBERGHE (56 Belgium), D. VANDIJCK (56 Belgium), W. VOGEL (40 Austria), I. WAKED (818 Egypt), H. WEDEMEYER (276 Germany), N. WEIS (208 Denmark), J. WIEGAND (208 Denmark), A. YOSRY (818 Egypt), A. ZEKRY (36 Australia), P. Van DAMME (56 Belgium), S. ALEMAN (752 Sweden) and S. J. HINDMAN (840 United States of America).
Edition JOURNAL OF VIRAL HEPATITIS, HOBOKEN, WILEY-BLACKWELL, 2014, 1352-0504.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30300 3.3 Health sciences
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 3.909
RIV identification code RIV/00216224:14110/14:00075463
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1111/jvh.12247
UT WoS 000333893200002
Keywords in English treatment; mortality; diagnosis; incidence; HCV; epidemiology; prevalence; hepatitis C; disease burden
Tags EL OK
Tags International impact, Reviewed
Changed by Changed by: Ing. Mgr. Věra Pospíšilíková, učo 9005. Changed: 13/5/2014 12:57.
Abstract
Chronic infection with hepatitis C virus (HCV) is a leading indicator for liver disease. New treatment options are becoming available, and there is a need to characterize the epidemiology and disease burden of HCV. Data for prevalence, viremia, genotype, diagnosis and treatment were obtained through literature searches and expert consensus for 16 countries. For some countries, data from centralized registries were used to estimate diagnosis and treatment rates. Data for the number of liver transplants and the proportion attributable to HCV were obtained from centralized databases. Viremic prevalence estimates varied widely between countries, ranging from 0.3% in Austria, England and Germany to 8.5% in Egypt. The largest viremic populations were in Egypt, with 6358000 cases in 2008 and Brazil with 2106000 cases in 2007. The age distribution of cases differed between countries. In most countries, prevalence rates were higher among males, reflecting higher rates of injection drug use. Diagnosis, treatment and transplant levels also differed considerably between countries. Reliable estimates characterizing HCV-infected populations are critical for addressing HCV-related morbidity and mortality. There is a need to quantify the burden of chronic HCV infection at the national level.
PrintDisplayed: 28/9/2024 06:24